Harpoon Therapeutics Says AbbVie Declines to Exercise License Option
September 13 2023 - 4:55PM
Dow Jones News
By Ben Glickman
Harpoon Therapeutics said on Wednesday that AbbVie won't
exercise its exclusive license option on Harpoon's HPN217
program.
The South San Francisco, Calif.-based immuno-oncology company
said that AbbVie had the option under an agreement between the two
companies, which is set to expire Oct. 12. Harpoon said that it
plans to complete the current Phase 1 trial in order to continue
development.
Harpoon's HPN217 program targets B cell maturation antigen.
Chief Executive Julie Eastland said that the preliminary data
"continue to be encouraging with a favorable safety profile."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 13, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024